1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
End-of-day quote Korea Stock Exchange  -  05-19
808000.00 KRW   +1.51%
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies; SK Hynix Loses 2%
MT
04/29SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
04/28South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3%
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Samsung to invest $206 bln by 2023 for post-pandemic growth

08/24/2021 | 02:36am EDT

SEOUL, Aug 24 (Reuters) - Samsung Group will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era, Samsung Electronics Co Ltd said.

The jewel of South Korea's biggest conglomerate on Tuesday said the investment through 2023 will help strengthen the group's global standing in key industries such as chip-making, while allowing it to seek growth opportunities in new areas such as robotics and next-generation telecommunications.

Samsung Electronics, the world's largest memory chip maker, said the group plans to solidify technology and market leadership through mergers and acquisitions. It did not provide a breakdown of the investment figures.

The firm did not say whether the latest investment figure includes the $17 billion it was reportedly spending on a new U.S. chip contract chip factory.

The plan is 30% larger than Samsung's previous three-year strategy floated in 2018. The group decided to increase investment to retain technological leadership, especially during "emergency situations" at home and abroad.

"The chip industry is the safety plate of the Korean economy... Our aggressive investment is a survival strategy in a sense that once we lose our competitiveness, it is almost impossible to make a comeback," Samsung Electronics said in a statement.

Chip rivals including Taiwan Semiconductor Manufacturing Co Ltd and Intel Corp are making large investments amid a global chip shortage and intensifying competition in the advanced chip segment.

Samsung Group has 59 affiliates with assets totalling 457 trillion won, according to South Korea's Fair Trade Commission.

The investment plan comes just over a week since Samsung Group leader Jay Y. Lee was released from jail on parole following convictions for bribery and embezzlement.

($1 = 1,167.0800 won) (Reporting by Heekyong Yang, Editing by Sherry Jacob-Phillips and Christopher Cushing)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
INTEL CORPORATION -0.86% 41.65 Delayed Quote.-19.13%
MSCI TAIWAN (STRD) 1.28% 603.833 Real-time Quote.-17.82%
SAMSUNG BIOLOGICS CO.,LTD. 1.51% 808000 End-of-day quote.-10.52%
SAMSUNG ELECTRONICS CO., LTD. 0.74% 68000 End-of-day quote.-13.15%
SAMSUNG SDI CO., LTD. 2.37% 605000 End-of-day quote.-7.63%
TAIWAN SEMICONDUCTOR CO., LTD. 0.60% 84 End-of-day quote.6.87%
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LIMITED 1.53% 530 End-of-day quote.-13.82%
All news about SAMSUNG BIOLOGICS CO.,LTD.
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies..
MT
04/29SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
04/28South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3%
MT
04/28Samsung Biologics' Net Income Surges 141% in March Quarter
MT
04/28Samsung Biologics Completes Full Acquisition Of Samsung Bioepis
AQ
04/27SAMSUNG BIOLOGICS : Material Business Matters Related to Investment Decisions
PU
04/21SAMSUNG BIOLOGICS : Results of issuance (Voluntary Disclosure)
PU
04/05Allakos Inc. Enters into A Master Development Services Agreement with Samsung Biologics..
CI
04/01Samsung C&T - Samsung Life Science Fund makes first investment in US biotech firm Jagua..
AQ
03/30SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2022 1 991 B 1,56 B 1,56 B
Net income 2022 542 B 0,43 B 0,43 B
Net Debt 2022 566 B 0,44 B 0,44 B
P/E ratio 2022 102x
Yield 2022 -
Capitalization 57 509 B 45 166 M 45 166 M
EV / Sales 2022 29,2x
EV / Sales 2023 25,6x
Nbr of Employees 2 886
Free-Float 25,6%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 808 000,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Seok-Woo Jung Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SAMSUNG BIOLOGICS CO.,LTD.-10.52%45 166
CSL LIMITED-5.75%93 148
WUXI BIOLOGICS (CAYMAN) INC.-43.60%30 261
BIOGEN INC.-16.78%29 239
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.71%22 130
UCB-13.28%17 367